Korean J Ophthalmol.  2018 Oct;32(5):400-408. 10.3341/kjo.2017.0127.

Influence of Vitrectomy-related Factors on the Outcome of Ahmed Glaucoma Valve Implantation

• Jo J
• Sung KR
• Kim YJ

• KMID: 2422070
• DOI: http://doi.org/10.3341/kjo.2017.0127

Abstract

PURPOSE
To evaluate the outcome of Ahmed glaucoma valve (AGV) implantation in eyes with refractory secondary glaucoma following pars plana vitrectomy (PPV) and the associated prognostic factors.
METHODS
A total of 146 eyes in 146 patients who underwent AGV implantation after PPV (followed up for ≥1 year) were included. AGV implantation was considered successful when the intraocular pressure (IOP) was 6 to 21 mmHg regardless of using IOP-lowering medication. The hazard ratios (HRs) associated with surgical failure were determined with Cox proportional analysis.
RESULTS
The most common cause for PPV was complications of proliferative diabetic retinopathy (50%). The mean and peak IOPs between PPV and AGV implantation were 26.9 ± 6.6 and 35.9 ± 10.2 mmHg, respectively. AGV implantation was performed on average 18.7 months after PPV, and its overall success rate was 80.1% during a mean follow-up period of 43.6 months. In multivariate analyses, rubeosis observed before AGV implantation (HR, 4.07; 95% confidence interval, 1.57 to 10.6; p = 0.004) and higher peak IOP before AGV (HR, 1.04; 95% confidence interval, 1.00 to 1.07; p = 0.034) were predictive of failure. However, no PPV-related factors were associated with the surgical outcome of AGV implantation.
CONCLUSIONS
The outcome of AGV implantation is good in refractory glaucoma following PPV. Rubeosis after PPV and higher peak IOP before AGV are risk factors for poor outcomes. Patients who undergo PPV should be followed for the development of rubeosis and IOP control.

Keyword

Ahmed glaucoma valve; Increased intraocular pressure; Vitrectomy

MeSH Terms

Diabetic Retinopathy
Follow-Up Studies
Glaucoma*
Humans
Intraocular Pressure
Multivariate Analysis
Risk Factors
Vitrectomy

Reference

1. Coleman AL, Hill R, Wilson MR, et al. Initial clinical experience with the Ahmed glaucoma valve implant. Am J Ophthalmol. 1995; 120:23–31.

2. Souza C, Tran DH, Loman J, et al. Long-term outcomes of Ahmed glaucoma valve implantation in refractory glaucomas. Am J Ophthalmol. 2007; 144:893–900.

3. Christakis PG, Tsai JC, Kalenak JW, et al. The Ahmed versus Baerveldt study: three-year treatment outcomes. Ophthalmology. 2013; 120:2232–2240.

4. Lee JY, Sung KR, Tchah HW, et al. Clinical outcomes after combined Ahmed glaucoma valve implantation and penetrating keratoplasty or pars plana vitrectomy. Korean J Ophthalmol. 2012; 26:432–437.

5. Nguyen QH, Lloyd MA, Heuer DK, et al. Incidence and management of glaucoma after intravitreal silicone oil injection for complicated retinal detachments. Ophthalmology. 1992; 99:1520–1526.

6. Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma. 2001; 10:237–249.

7. Takihara Y, Inatani M, Fukushima M, et al. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol. 2009; 147:912–918.

8. Han DP, Lewis H, Lambrou FH Jr, et al. Mechanisms of intraocular pressure elevation after pars plana vitrectomy. Ophthalmology. 1989; 96:1357–1362.

9. Honavar SG, Goyal M, Majji AB, et al. Glaucoma after pars plana vitrectomy and silicone oil injection for complicated retinal detachments. Ophthalmology. 1999; 106:169–176.

10. Aaberg TM, Van Horn DL. Late complications of pars plana vitreous surgery. Ophthalmology. 1978; 85:126–140.

11. Won HJ, Sung KR. Hypertensive phase following silicone plate ahmed glaucoma valve implantation. J Glaucoma. 2016; 25:e313–e317.

12. Hong JW, Choi GJ. Ahmed valve implantation for refractory glaucoma following pars plana vitrectomy. Korean J Ophthalmol. 2005; 19:293–296.

13. Sidoti PA, Dunphy TR, Baerveldt G, et al. Experience with the Baerveldt glaucoma implant in treating neovascular glaucoma. Ophthalmology. 1995; 102:1107–1118.

14. Ishida K, Ahmed II, Netland PA. Ahmed glaucoma valve surgical outcomes in eyes with and without silicone oil endotamponade. J Glaucoma. 2009; 18:325–330.

15. Park UC, Park KH, Kim DM, Yu HG. Ahmed glaucoma valve implantation for neovascular glaucoma after vitrectomy for proliferative diabetic retinopathy. J Glaucoma. 2011; 20:433–438.

16. Summanen P. Neovascular glaucoma following vitrectomy for diabetic eye disease. Acta Ophthalmol (Copenh). 1988; 66:110–116.

17. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007; 18:502–508.

18. Moraczewski AL, Lee RK, Palmberg PF, et al. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol. 2009; 93:589–593.

19. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008; 115:1571–1580.

20. Kwon J, Sung KR. Effect of preoperative intravitreal bevacizumab on the surgical outcome of neovascular glaucoma at different stages. J Ophthalmol. 2017; 2017:7672485.

21. Al-Jazzaf AM, Netland PA, Charles S. Incidence and management of elevated intraocular pressure after silicone oil injection. J Glaucoma. 2005; 14:40–46.